{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.0","upperLimit":"23.3","value":"15.6"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"17.8","value":"12.7"},{"groupId":"OG002","lowerLimit":"5.3","upperLimit":"26.1","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"Evaluate overall survival (OS)","dispersionType":"95% Confidence Interval","groups":[{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)","id":"OG000","title":"Cohort 2"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)","id":"OG001","title":"Cohort 4"},{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product)","id":"OG002","title":"Cohort 1"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set is defined as patients who received the lifileucel infusion that met product manufacturing specifications. Due to the small number of patients this outcome measure was not analyzed for Cohort 3 per the statistical analysis plan.","reportingStatus":"POSTED","timeFrame":"Until death or up to 60 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}